Page 21 - GPD-3-4

Gene & Protein in Disease Human sirtuins (SIRT1-7) in cancer

105. Khongkow M, Olmos Y, Gong C, et al. SIRT6 modulates 116. Zhao Q, Zhou J, Li F, et al. The role and therapeutic
paclitaxel and epirubicin resistance and survival in breast perspectives of sirtuin 3 in cancer metabolism
cancer. Carcinogenesis. 2013;34(7):1476-1486. reprogramming, metastasis, and chemoresistance. Front
doi: 10.1093/carcin/bgt098 Oncol. 2022;12:910963.
106. Wang L, Guo W, Ma J, et al. Aberrant SIRT6 expression doi: 10.3389/fonc.2022.910963
contributes to melanoma growth: Role of the autophagy paradox 117. Ianni A, Kumari P, Tarighi S, Braun T, Vaquero A. SIRT7:
and IGF-AKT signaling. Autophagy. 2018;14(3):518-533. A novel molecular target for personalized cancer treatment?
doi: 10.1080/15548627.2017.1384886 Oncogene. 2024;43(14):993-1006.
107. Cagnetta A, Soncini D, Orecchioni S, et al. Depletion of doi: 10.1038/s41388-024-02976-8
SIRT6 enzymatic activity increases acute myeloid leukemia 118. Chen PT, Yeong KY. New sirtuin modulators: Their
cells’ vulnerability to DNA-damaging agents. Haematologica. uncovering, pharmacophore, and implications in drug
2018;103(1):80-90. discovery. Med Chem Res. 2024;33:1064-1078.
doi: 10.3324/haematol.2017.176248 doi: 10.1007/s00044-024-03249-5
108. Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential 119. Deus CM, Serafim TL, Magalhães-Novais S, et al. Sirtuin
in human hepatocellular carcinoma and its regulation by the 1-dependent resveratrol cytotoxicity and pro-differentiation
tumor suppressors MiR-125a-5p and MiR-125b. Hepatology. activity on breast cancer cells. Arch Toxicol. 2017;91(3):1261-1278.
2013;57(3):1055-1067.
doi: 10.1007/s00204-016-1784-x
doi: 10.1002/hep.26101
120. Li L, Fu S, Wang J, et al. SRT1720 inhibits bladder cancer
109. Monteiro-Reis S, Lameirinhas A, Miranda-Gonçalves V, et al. cell progression by impairing autophagic flux. Biochem
Sirtuins’ deregulation in bladder cancer: SIRT7 is implicated Pharmacol. 2024;222:116111.
in tumor progression through epithelial to mesenchymal
transition promotion. Cancers (Basel). 2020;12(5):1066. doi: 10.1016/j.bcp.2024.116111
doi: 10.3390/cancers12051066 121. Tan P, Wang M, Zhong A, et al. SRT1720 inhibits the growth
of bladder cancer in organoids and murine models through
110. Paredes S, Villanova L, Chua KF. Molecular pathways: the SIRT1-HIF axis. Oncogene. 2021;40(42):6081-6092.
Emerging roles of mammalian Sirtuin SIRT7 in cancer. Clin
Cancer Res. 2014;20:1741-1746. doi: 10.1038/s41388-021-01999-9
doi: 10.1158/1078-0432.CCR-13-1547 122. Fatehi D, Soltani A, Ghatrehsamani M. SRT1720, a potential
sensitizer for radiotherapy and cytotoxicity effects of NVB-
111. Huo Q, Chen S, Zhuang J, Quan C, Wang Y, Xie N. SIRT7
downregulation promotes breast cancer metastasis via BEZ235 in metastatic breast cancer cells. Pathol Res Pract.
LAP2α-induced chromosomal instability. Int J Biol Sci. 2018;214(6):889-895.
2023;19(5):1528-1542. doi: 10.1016/j.prp.2018.04.001
doi: 10.7150/ijbs.75340 123. Han L, Long Q, Li S, et al. Senescent stromal cells
112. Wang HL, Lu RQ, Xie SH, et al. SIRT7 exhibits oncogenic promote cancer resistance through SIRT1 loss-potentiated
potential in human ovarian cancer cells. Asian Pac J Cancer overproduction of small extracellular vesicles. Cancer Res.
Prev. 2015;16(8):3573-3537. 2020;80(16):3383-3398.
doi: 10.7314/apjcp.2015.16.8.3573 doi: 10.1158/0008-5472.CAN-20-0506
113. Liu X, Li C, Li Q, Chang HC, Tang YC. SIRT7 facilitates 124. Chowdhury S, Sripathy S, Webster A, et al. Discovery of
CENP-A nucleosome assembly and suppresses intestinal selective SIRT2 inhibitors as therapeutic agents in B-cell
tumorigenesis. iScience. 2020;23(9):101461. lymphoma and other malignancies. Molecules. 2020;25(3):455.
doi: 10.1016/j.isci.2020.101461 doi: 10.3390/molecules25030455
114. Yu H, Ye W, Wu J, et al. Overexpression of sirt7 exhibits 125. Hirai S, Endo S, Saito R, et al. Antitumor effects of a sirtuin
oncogenic property and serves as a prognostic factor in inhibitor, tenovin-6, against gastric cancer cells via death
colorectal cancer. Clin Cancer Res. 2014;20(13):3434-3445. receptor 5 up-regulation. PLoS One. 2014;9(7):e102831.
doi: 10.1158/1078-0432.CCR-13-2952 doi: 10.1371/journal.pone.0102831
115. Tang M, Lu X, Zhang C, et al. Downregulation of SIRT7 by 126. Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators
5-fluorouracil induces radiosensitivity in human colorectal and inhibitors: Promises, achievements, and challenges.
cancer. Theranostics. 2017;7(5):1346-1359. Pharmacol Ther. 2018;188:140-154.
doi: 10.7150/thno.18804 doi: 10.1016/j.pharmthera.2018.03.004

Volume 3 Issue 4 (2024) 13 doi: 10.36922/gpd.4100